Polypharmacy in relation to the most frequent conditions | Median (IQR) | p-value a | |
Chronic conditions | n drugs in patients with the condition | n drugs in patients without the condition | Â |
Hypertension | 9 (8 – 11) | 9 (8 – 10) | 0.081 |
Arthrosis | 10 (8 – 11) | 9 (8 – 10) | < 0.001 |
Diabetes mellitus II | 9 (8 – 11) | 9 (8 – 10) | 0.004 |
Dyslipidaemia | 9 (8 – 11) | 9 (8 – 11) | 0.901 |
Atrial fibrillation | 9 (8 – 11) | 9 (8 – 11) | 0.721 |
Coronary heart disease | 10 (8 – 11) | 9 (8 – 10) | 0.006 |
Osteoporosis | 9 (8 – 11) | 9 (8 – 11) | 0.292 |
Depression | 9 (8 – 11) | 9 (8 – 11) | 0.051 |
Benign prostatic hypertrophy | 9 (8 – 11) | 9 (8 – 11) | 0.255 |
Gastro-oesophageal reflux disease | 9 (8 – 10) | 9 (8 – 11) | 0.885 |
Chronic heart failure | 9 (8 – 11) | 9 (8 – 11) | 0.443 |
Chronic obstructive pulmonary disease (COPD) | 10 (8 – 12) | 9 (8 – 10) | 0.016 |
Chronic renal failure | 9 (8 – 11) | 9 (8 – 11) | 0.158 |
Hyperuricaemia and/or gout | 9.5 (9 – 11) | 9 (8 – 11) | 0.148 |
Hypothyroidism | 9 (8 – 11) | 9 (8 – 11) | 0.472 |
Insomnia | 9 (8 – 11) | 9 (8 – 11) | 0.923 |
Cerebrovascular disease | 9 (8 – 11) | 9 (8 – 11) | 0.986 |
Polypharmacy in relation to the most frequent drug classes | Median (IQR) | p-value a | |
Drug classes | n drugs in patients with the drug class | n drugs in patients without the drug class | Â |
ARBs/ACE-inhibitors | 9 (8 – 11) | 9 (8 – 10) | 0.137 |
PPIs | 9 (8 – 11) | 9 (8 – 10) | < 0.001 |
Statins | 9 (8 – 11) | 9 (8 – 10) | 0.257 |
Platelet-aggregation inhibitors | 9 (8 – 11) | 9 (8 – 10) | 0.056 |
Beta-blockers | 9 (8 – 11) | 9 (8 – 10) | 0.461 |
Minor diuretics (predominantly hydrochlorothiazide) | 9 (8 – 11) | 9 (8 – 11) | 0.642 |
CCBs | 10 (8 – 11) | 9 (8 – 10) | 0.004 |
Loop diuretics (predominantly Furosemide) | 10 (9 – 11) | 9 (8 – 10) | < 0.001 |
Vitamins (predominantly vit. D) | 10 (8 – 11) | 9 (8 – 10) | < 0.001 |
Antidepressants | 10 (9 – 12) | 9 (8 – 10) | < 0.001 |
Oral anticoagulants | 9 (8 – 11) | 9 (8 – 11) | 0.620 |
Anxiolytics/hypnotics (Benzodiazepines + Zolpidem) | 10 (8 – 11) | 9 (8 – 10) | < 0.001 |
Dietary supplements (predominantly Calcium) | 10 (9 – 11) | 9 (8 – 10) | < 0.001 |
Oral antidiabetic drugs | 9.5 (8 – 11) | 9 (8 – 10) | 0.018 |
Antiasthmatic agents, beta-adrenergics, anticholinergics | 10 (9 – 12) | 9 (8 – 10) | < 0.001 |
Opioids | 10 (9 – 12) | 9 (8 – 10) | < 0.001 |
Analgesics - Paracetamol | 9 (8 – 11) | 9 (8 – 11) | 0.385 |
Thyroid hormones | 10 (8 – 11) | 9 (8 – 10) | 0.009 |
Corticosteroids | 10 (9 – 12) | 9 (8 – 10) | < 0.001 |
NSAIDs + COX-2-inhibitors (Coxibe) | 9 (8 – 10) | 9 (8 – 11) | 0.716 |